Abstract
Distinct subclones within mammary tumors functionally cooperate in a WNT-driven model system.
Major Finding: Distinct subclones within mammary tumors functionally cooperate in a WNT-driven model system.
Concept: Wnt1low basal subclones rely on and recruit Wnt1high luminal cells to maintain oncogenic signaling.
Impact: Clonal cooperation in human tumors may affect clinical behavior and response to therapeutics.
Intratumoral heterogeneity is a common feature of many human malignancies, including breast cancer, but its relevance to tumor initiation or maintenance is unclear. To gain insight into the relationship of individual subclones within a tumor, Cleary and colleagues utilized a mouse model system in which mammary tumors are driven by Wnt1 transgene expression and are characterized by the coexistence of both low Wnt1-expressing (Wnt1low) basal and high Wnt1-expressing (Wnt1high) luminal lineages. A subset of Wnt1-induced tumors spontaneously acquired somatic Hras mutations restricted to the basal cell subtype, suggesting a biclonal configuration; however, both lineages were required for tumor formation in secondary recipients and depended on Wnt1 expression by luminal cells. In a related mouse model with doxycycline (DOX)-inducible Wnt1 (iWNT) expression, biclonal mammary tumors regressed upon DOX withdrawal. However, iWNT-derived Hras-mutant basal tumor cells transplanted into mice constitutively expressing Wnt1 only partially regressed upon DOX withdrawal and spontaneously relapsed. In relapsed tumors, host-derived Hras–wild-type Wnt1high luminal cells were invariably recruited by and intermingled with donor Wnt1lowHras-mutant basal tumor cells, suggesting that Hras-mutant Wnt1low donor basal subclones recruited host luminal epithelial cells to serve as a source of WNT1. In the absence of a substitute WNT1 source, DOX-deprived iWNT tumors regressed but frequently relapsed weeks later as DOX-independent tumors, mimicking acquired resistance to targeted therapy. The WNT pathway was reactivated in the majority of DOX-independent tumors, either through mutations that allowed DOX-independent WNT1 transgene expression or through activating mutations in Ctnnb1, which encodes the WNT1 downstream effector β-catenin. Taken together, these studies provide evidence for interclonal cooperation during tumor progression that suggests a nonhierarchical mechanism for maintenance of tumor heterogeneity that may inform therapeutic strategies and studies of tumor evolution.
Note: Research Watch is written by Cancer Discovery Science Writers. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.